Zhang G J, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S
Department of Clinical Oncology, National Cancer Center Hospital and Research Institute, Tokyo, Japan.
Jpn J Clin Oncol. 1997 Dec;27(6):371-7. doi: 10.1093/jjco/27.6.371.
Patients with primary breast carcinoma with one to three axillary lymph node metastases but without distant metastases (n1-3) in Japan have been shown to have a 10-year disease-free survival rate of > 60%. It would be reasonable to divide n1-3 Japanese breast cancer patients into groups with high- or low-risk for recurrence and to consider post-operative adjuvant therapy. In the present study, we analyzed 228 consecutive Japanese patients with n1-3 breast cancer who underwent radical mastectomy and were followed up for a median time of 11.0 years. The expression of bcl-2, p53 and c-erbB-2 proteins in the primary tumors was examined immunohistochemically and their prognostic roles were also analyzed along with conventional clinicopathologic indicators. bcl-2 expression was correlated with positive estrogen receptor status and inversely correlated with p53, c-erbB-2 and histologic grade. Univariate analysis showed that bcl-2, p53 and c-erbB-2 expression were prognostic indicators of the patient's group as well as node status, histologic grade, tumor size, age at diagnosis, menopausal status and estrogen receptor status. Cox's regression analysis demonstrated that the number of nodes involved, menopausal status, p53 and bcl-2 were independent predictors for overall survival and that histologic grade and the number of nodes involved were independent predictors for disease-free survival. These results suggest that bcl-2 expression in combination with p53 and c-erbB-2 expression, the number of lymph node metastases, histologic grade and menopausal status are useful in selecting subgroups of n1-3 breast cancer patients with good or poor prognoses.
在日本,患有原发性乳腺癌且有一至三个腋窝淋巴结转移但无远处转移(n1 - 3)的患者,其10年无病生存率已被证明大于60%。将n1 - 3期日本乳腺癌患者分为复发高风险或低风险组并考虑术后辅助治疗是合理的。在本研究中,我们分析了228例连续的n1 - 3期日本乳腺癌患者,这些患者接受了根治性乳房切除术,并进行了中位时间为11.0年的随访。通过免疫组织化学检查原发性肿瘤中bcl - 2、p53和c - erbB - 2蛋白的表达,并结合传统临床病理指标分析它们的预后作用。bcl - 2表达与雌激素受体阳性状态相关,与p53、c - erbB - 2和组织学分级呈负相关。单因素分析表明,bcl - 2、p53和c - erbB - 2表达以及淋巴结状态、组织学分级、肿瘤大小、诊断时年龄、绝经状态和雌激素受体状态都是患者组的预后指标。Cox回归分析表明,受累淋巴结数量、绝经状态、p53和bcl - 2是总生存的独立预测因素,组织学分级和受累淋巴结数量是无病生存的独立预测因素。这些结果表明,bcl - 2表达结合p53和c - erbB - 2表达、淋巴结转移数量、组织学分级和绝经状态,有助于选择n1 - 3期乳腺癌患者中预后良好或不良的亚组。